ViroCell Biologics

ViroCell manufactured a GMP lentiviral vector for UCL to accelerate research into prevention of relapse in childhood blood cancer

UCL leveraged ViroCell’s expertise in lentiviral vector manufacturing for an innovative CAR T-cell therapy for the treatment of paediatric acute lymphoblastic leukaemia 17 April 2025 -- London, UK and New York, US -- ViroCell Biologics, a specialist viral vector Contract Development and Manufacturing Organisation (“CDMO”) for cell and gene therapy (CGT) clinical trials, announces the...

ViroCell Biologics signs Master Services Agreement with prominent NCI-designated cancer centre

MSA enables collaboration on full suite of ViroCell’s viral vector manufacturing services to accelerate the cancer centre’s clinical development of novel gene-modified cell therapies Agreement follows ViroCell’s successful GMP manufacture and release of a lentivirus vector for the cancer centre’s clinical evaluation of a novel engineered TCR therapy. 22 July 2024 -- London, UK, and...

ViroCell signs manufacturing services agreement with UCL to accelerate research into prevention of relapse in childhood blood cancer

Agreement will leverage ViroCell’s expertise in lentiviral vector manufacturing for an innovative CAR T-cell therapy for the treatment of paediatric acute lymphoblastic leukaemia 12 December 2023 -- London, UK and New York, US -- ViroCell Biologics, a specialist viral vector Contract Development and Manufacturing Organisation (CDMO) for cell and gene therapy (CGT) clinical trials, announces...